Recently, Ma et al. described that FLT3 inhibitors such as midostaurin and gilteritinib sensitize FLT3-ITD de novo AML cells to venetoclax by reducing MCL1 expression34. The gene discussed is FLT3; the disease is acute myeloid leukemia.